免疫组化在肝癌诊断中的应用

Diagnostic Value of Immunohistochemical for Hepatic Cancer

目的:探讨免疫组化在肝癌诊断中的作用。方法:遴选我院178例肝癌患者,其中PHC组90例,继发性肝癌组88例和90例健康人作为对照。测定每组AFP、AFU、SF和CA19-9的检测水平以及各项标志物联检的水平。结果:PHC组各项值明显呈阳性,正常对照组均呈阴性,继发性肝癌组居中。PHC组AFP的阳性检出率为78.89%,AFU的阳性检出率为65.56%,SF的阳性检出率为53.33%,CA19-9的阳性检出率为58.89%,各项联检的阳性检出率为95.56%。结论:AFP、AFU、SF和CA19-9联合检测能大大提高肝癌的检出率,有助于PHC的早期诊断和治疗。

ABSTRACT Objective： To probe the diagnostic value ofimmunohistochemical for hepatic cancer. Methods： We select 178 cases of patients with hepatic cancer. There are 90 examples in the PHC group, and 88 examples in the secondary hepatic cancer group. There are 90 cases of healthy controls. We determine the level of AFP, AFU, SF and CA19-9 in each group, and the level of the joint markers detection. Results： The level of AFP, AFU, SF and CA19-9 are significantly positive in the group of PHC, and are negative in normal control group, and are in center in the group of secondary hepatic cancer. In PHC group, the positive detection rate of AFP is 78.89%, the positive detection rate of AFU is 65.56%, the positive detection rate of SF is 53.33%, and the positive detection rate of CA19-9 is 58.89%. The positive detection rate of the joint markers is 95.56%. Conclusion： AFP, AFU, SF, and CA19-9 united detection can dramatically improve the detection rate of hepatic cancer, and can help early diagnosis and treatment of the PHC. Key words： PHC; AFP; AFU; SF; CA19-9